CHDR
Centre for Human Drug Research

Centrale Commissie Mensgebonden Onderzoek (CCMO)
tav bevoegde instantie (BI)
Parnassusplein 5
2511 VX Den Haag

Leiden, 11-Oct-2021
Ref.: End of Trial (EoT) Notification for research dossier – CHDR1822 (NL71107.056.19)

Dear members of the CCMO,

With this letter I would like to inform the Competent Authority about the end of the clinical phase of the study CHDR1822 titled: "*A first-in-human, randomized, subject-blinded, placebo controlled, single ascending dose study to investigate the safety, tolerability and pharmacokinetics of MHS552 in healthy*", which is registered under NL71107.056.19.

The clinical phase of this study started on 08-Oct-2019 (screening of first subject) and ended on 06-Aug-2021 (last follow-up visit).

The conduct of the study was successful. There has been one SAE.

The summary of the clinical study report will be submitted according to 'Directive 2001/20/EC'. Enclosed you will also find the EudraCT "Declaration of the end of trial form".

Please do not hesitate to contact us in case of any questions.

Kind regards,

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

Enclosed
Electronic copy of the B7. End of clinical phase form via mail